AVRAnteris Technologies Global Corp.
Anteris Technologies Global Corp. (AVR) sells structural heart devices, primarily focused on transcatheter aortic valve replacement (TAVR) solutions. The next catalyst is Dec 22, 2026 — PARADIGM Trial Interim Data Readout / Regulatory Update, which will test the company’s ability to deliver meaningful clinical data and navigate regulatory hurdles.
- The company has reported negative net income and free cash flow, with revenue declining year-over-year.
- Shareholders’ equity is negative, and leverage is non-existent, suggesting a capital-light model with high operational risk.
- The business is heavily dependent on the success of its PARADIGM trial, with no other revenue streams or product launches in the near term.
The Read
Following improved financial guidance and clinical progress in Q4 2025, AVR's stock surged 17.
The schedule
- Tue10Nov
The earnings release will test the ability to meet or exceed revenue and EPS guidance, with a focus on margin expansion and cash flow generation. This differs from the last print where the company underperformed on margin commentary.
- Tue22Dec
The interim data readout will test the company's ability to demonstrate progress in its PARADIGM trial, which could influence investor sentiment and regulatory momentum.
- Tue26Jan
The capital raise will test the company's ability to secure funding for its key trial, which is critical for advancing its pipeline and maintaining investor confidence.
- Sun7Feb
The capital raise will test the company's ability to leverage Medtronic's backing to advance its key trial, which is essential for long-term growth and regulatory progress.
- Sun7Feb
The clinical data presentation will test the company's ability to showcase the effectiveness of its TCT 2026 trial, which is a key milestone in its development timeline.
- Wed10Mar
The investor presentations will test the company's ability to communicate its strategic vision and financial outlook, which is crucial for maintaining investor confidence and attracting new capital.
- Wed10Mar
The earnings release will test whether the company can deliver consistent guidance and margin expansion, unlike the last print where revenue growth was underwhelming.
- Tue11May
This release will test the company's ability to sustain cash flow and expand margins, with a focus on the recent equity raise's impact on balance sheet strength.
- Mon9Aug
The earnings release will test the company's ability to maintain cash flow and deliver on its growth strategy, especially with the recent equity raise and potential product launches.
- Wed10Nov
This release will test the company's ability to deliver on its long-term growth strategy, with a focus on product launches and revenue diversification.
Past
- Wed2Sep
Actual outcome: Bear · $8.38 at outcome
The stock fell 2.6% following the Medtronic partnership announcement, likely due to mixed market sentiment. While the strategic partnership with Medtronic was positive, the stock price declined, suggesting investors were cautious about the long-term impact of the deal and potential challenges in execution. The price action indicates a bearish reaction to the event.
Strategic partnership announcement with Medtronic, potentially boosting investor sentiment.
- Tue11Aug
Actual outcome: Mixed · $8.89 at outcome
The stock fell 3.1% following the earnings release, despite the EPS matching estimates. The positive news around the event date, such as the share price rise after market close, did not sustain, and the stock continued to decline toward the bear floor. The lack of positive catalysts and the failure to meet investor expectations in terms of guidance and strategic developments led to the bearish movement.
- Tue12May
Actual outcome: Bull · $7.24 at outcome
Anteris met Q1 EPS expectations at -$0.93 and reported strong operational progress, highlighted by the successful treatment of the first US patients in its DurAVR pivotal PARADIGM trial. The market reacted positively to these significant clinical milestones and the strengthening of the board, which overshadowed concerns regarding the company's cash burn rate and drove the stock well above the bull target.
- Wed25Mar
Actual outcome: Bear · $5.11 at outcome
Shares declined 7.6% during the outcome window as investors weighed the risks of a potential dilutive capital raise or strategic financing. The lack of immediate clarity regarding the financing terms created an overhang on the stock, driving the near-term sell-off before broader attention shifted to the company's structural heart valve developments in early April.
- Thu26Feb
Actual outcome: Bull · $6.62 at outcome
AVR reported EPS of -0.62, matching estimates, but provided stronger-than-expected financial guidance following the Q4 2025 earnings release. The post-raise guidance signaled improved demand and operational stability, which drove the stock higher and surpassed the bull target of $6.45.